Toward Acceleration of Open Innovation
|
|
- Leon Parker
- 8 years ago
- Views:
Transcription
1 Toward Acceleration of Open Innovation ーThe Role of Industrial-Academic- Government-Collaborationー Masafumi Nogimori Representative Director and Chairman Astellas Pharm Inc. International Symposium New Approach for Medical R&D Aug
2 2 1. Changes in Drug Discovery Environment 2. Importance of Partnership in Drug Discovery 3. Introduction of Innovative Collaborations 4. Proposal to Construct New Collaboration
3 3 1.Changes in Drug Discovery Environment Drug Discovery Environment Drug Targets Drug targets that regulate more complex functions Technology Emerging diverse technologies, such as regenerative medicine and gene therapy Approval Process Clear differentiation against existing drugs and stricter safety standards Increasing difficulty in research Rising investment Higher hurdles for approval Development of new drugs is becoming more difficult due to greater challenges in the drug discovery environment
4 R&D Expenditures Number of NMEs(FDA) 4 Increased R&D costs 60, , , , , , R&D Expenditures of PhRMA($M) Number of NMEs R&D Expenditures of JPMA ( 00M) References:JPMA DATA BOOK, PhRMA Industry Profile, FDA HP Source:The Office of Pharmaceutical Industry Research (OPIR) New drug approval rates stagnant and R&D costs are increasing, making it difficult to sustain the conventional business model
5 2. Importance of Partnership in Drug Discovery Open Innovation(OI) Definition * A paradigm that assumes that firms can and should use external ideas as well as internal ideas, and internal and external paths to market, as they look to advance their technology Effects Knowledge integration Synergy Efficiency Research concept Cutting-edge technology Expertise Creative ideas Different cultures Expanded network Cost reduction R&D risk management Shared infrastructure Integration of knowledge in each company is essential Construction of efficient collaboration is needed Renovation of the mind is important for further enhancement of OI *reference:chesbrough, Henry William. Open Innovation: The new imperative for creating and profiting from technology. 5
6 3.Introduction of Innovative Collaborations Japan Compound Library Consortium(J-CLIC) 6 Compound library is; A collection of stored chemical compounds used in high-throughput screening (HTS) J-CLIC Launched in April companies participate First successful collaboration between pharmaceutical companies for constructing a compound library Integration of industrial know-how to construct an innovative and high quality library
7 Drug Discovery with Big Data Big Data is; Massive volumes of data that is too big and complicated to handle using traditional database and software Support for health maintenance Healthy Persons, Patients Medical services Health examination Utilization Preventive Medicine Biomarker Discovery Target Discovery Precision Medicine Gathering Big Data Electrical Health Records Personal Health Records Genome Omics Data Definition and re-categorization of diseases Data Management and Analysis Method establishment to handle Big Data Big Data utilization is essential for novel drug target discovery and early diagnosis Due to differences corporate strategies, there is little consensus regarding Big Data utilization 7
8 8 Comparison between J-CLIC and Big Data Consortium J-CLIC Big Data Purpose Basic Technology Collaboration Structure Hit discovery using HTS Equipped in each company Pharma companies only Preventive Medicine, Biomarker discovery Dispersed in various institutions Pharma companies and various institutions Expenditure Within running costs Huge investment Expected Outcome Promoting innovation with shared know-how Promoting innovation in new fields with cuttingedge technology
9 9 4.Proposal to Construct New Collaboration Proposals to the industry Strategy Developing an overall strategy to expand collaboration in pre-competitive and leading edge areas OI mind-set Audacious open-mind to open innovation and pre-competitive collaboration Funding Sharing costs among industries with government support Human resources Training experts in the area of open innovation
10 10 Expectations of Government and Academia Control Function Strong Leadership for the Industry-Academia-Government collaboration in the field of medical research. AMED Bio bank, Regenerative medicine and Oncology etc. PMDA Regulatory science and Partnership with Asian countries NIBIO Center for Drug Design Research AIST LEAD Riken Supercomputer and Spring-8 etc. Cultivation of Human Resources Alliance management expertise Cultivation of Ventures Continual and long-term support AMED, PMDA, NIBIO, AIST, Riken
What Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationHow Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA
How Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA September 10, 2013 Outline Need for improved science in support of
More informationAn Introduction to Genomics and SAS Scientific Discovery Solutions
An Introduction to Genomics and SAS Scientific Discovery Solutions Dr Karen M Miller Product Manager Bioinformatics SAS EMEA 16.06.03 Copyright 2003, SAS Institute Inc. All rights reserved. 1 Overview!
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationThe Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder
The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system
More informationOpen Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum
Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities
More informationTIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials
TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization
More informationIn the largest and perhaps the most ambitious collaborative
FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated
More informationINVESTMENT IN DISRUPTIVE EXPONENTIAL TECHNOLOGIES
INVESTMENT IN DISRUPTIVE EXPONENTIAL TECHNOLOGIES Deep Knowledge Ventures Deep Knowledge Ventures is a Hong Kong investment fund focusing on biotechnology, regenerative medicine, drug discovery, Artificial
More informationBig Data An Opportunity or a Distraction? Signal or Noise?
Big Data An Opportunity or a Distraction? Signal or Noise? Maya R. Said, Sc.D. SVP & Global Head, Oncology Policy & Market Access, Novartis 3rd International Systems Biomedicine Symposium Luxembourg, 28
More informationIntroduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)
Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and
More informationNational Institute of Public Health
National Institute of Public Health Human resource development and research to improve public health Aiming for a healthy and safe society National Institute of Public Health website: http://www.niph.go.jp/index_en.html
More informationThe Healthcare Policy and The New System of Medical R&D
The Healthcare Policy and The New System of Medical R&D Jun, 2013 14 th Japan Revitalization Strategy, Cabinet decision The Healthcare Policy, agreement among Ministers related Jul Progress and Achievements
More informationQuality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationHow To Change Medicine
P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything Leroy E. Hood Institute for Systems Biology David J. Galas Battelle Memorial Institute Version
More informationHealthcare Innovation in the UK - A Royal Society of Chemistry Position Paper
Healthcare Innovation in the UK - A Royal Society of Chemistry Position Paper Introduction The pharmaceutical industry (Pharma) has made important contributions to quality of life, longevity, economic
More informationMedium Term Management Plan Next 100 Transform to Grow
Medium Term Management Plan Conference in Tokyo (June 17, 2014) NIKON CORPORATION Forward-looking statements for earnings and other performance data contained herein are based on information currently
More informationA career on the science park
A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort
More informationPersonalized medicine in China s healthcare system
Personalized medicine in China s healthcare system Jingmin Kan, Sam Linsen Netherlands office for Science and Technology, Guangzhou and Shanghai, China Content PERSONALIZED MEDICINE 2 FOCUS AT THE INDIVIDUAL
More informationPERSPECTIVE Drug Discovery Today Volume 17, Numbers 13/14 July 2012
drug development: an economically viable strategy for biopharma R&D feature Kiran N. Meekings 1, kiran.meekings@thomsonreuters.com, Cory S.M. Williams 2 and John E. Arrowsmith 1 drug incentives have stimulated
More informationEnabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV
Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationHigh-Throughput Screening at The University of Chicago Cellular Screening Center. Sam Bettis Technical Director sbettis@bsd.uchicago.
igh-throughput Screening at The University of Chicago Cellular Screening Center Sam Bettis Technical Director sbettis@bsd.uchicago.edu igh-throughput Screening at The University of Chicago! Cellular Screening
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationAccelerating Development and Approval of Targeted Cancer Therapies
Accelerating Development and Approval of Targeted Cancer Therapies Anna Barker, NCI David Epstein, Novartis Oncology Stephen Friend, Sage Bionetworks Cindy Geoghegan, Patient and Partners David Kessler,
More information1) SCOPE OF THE PROGRAM
CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany
More informationNIH Center for Regenerative Medicine
Catalyzing stem cell-based translation and therapy development Story Landis, Ph.D. Director, National Institute of Neurological Disorders and Stroke Council of Councils Meeting August 15, 2011 Center for
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationCorporate Overview. Dr Robert Scoffin CEO. http;//www.re-pharm.com/ STAND NUMBER: 27 rob@re-pharm.com
Corporate Overview Dr Robert Scoffin CEO http;//www.re-pharm.com/ STAND NUMBER: 27 rob@re-pharm.com Re-Pharm Summary > Focus on commercially valuable early stage assets. > Repositioned compounds > Using
More informationEngineering for the new pharma reality
NNE Pharmaplan is an international company specialised in pharma engineering. We help pharmaceutical companies bring products to market by providing flexible, compliant and future-proof solutions. We have
More informationCDISC Strategy Document Version 9 (Final BOD Approved Version) 4 December 2006
CDISC Strategy Document Version 9 (Final BOD Approved Version) 4 December 2006 Introduction The Clinical Data Interchange Standards Consortium (CDISC) has established standards to support the acquisition,
More information2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
More informationEnabling Anti-Fungal Discovery Through Advanced Biocomputation Tools
Enabling Anti-Fungal Discovery Through Advanced Biocomputation Tools Fungal Infestations and Infections A Massive Cause of Agricultural Loss Worldwide Rice Blast Corn Rust Botrytis Rot FOOD INSECURITY
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More information5HJHQDWLYH 0HGLFLQH,QGXVWU\ LQ -DSDQ
(updated:2015/5/18) Rapid Growth of the Japanese Regenerative Medicine Industry Japan is the second-largest pharmaceutical market (2012) in the world after the United States. METI estimates the market
More informationPfizer Oncology. Guest Expert: Louis Denis, MD Director of Clinical Research, Pfizer Oncology. www.wnpr.org. www.yalecancercenter.
Pfizer Oncology Guest Expert: Louis, MD Director of Clinical Research, Pfizer Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken Miller. I am Bruce
More informationCall 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
More informationA Core Clinical Research Hospital to provide world class advanced medical care
Basic Principals 1 2 3 Providing safe and highquality medical care as a patient-centered hospital Contributing to society through the development and practice of new treatments Fostering medical professionals
More informationDonna J. Dean, Ph.D. October 27, 2009 Brown University
Building Connections with NIH Program Officers: Myths and Realities Donna J. Dean, Ph.D. October 27, 2009 Brown University Funding Agencies Federal Agencies Focused on Biomedical Research s of Health (NIH)
More informationDrug Development Models in China and the Impact on Multinational Pharmaceutical Companies
Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial
More informationMedicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
More informationBrand Quality with Asian Advantages
Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com
More informationAcademic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery
Academic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery www.pharmacy.unc.edu/cicbdd Stephen V. Frye, Ph.D. University of North Carolina Chapel Hill Outline Why Academic
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationClinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.
Clinical Trial Trends Outline Complexity for Supply Chain Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.com 29 May 2013 Biotechnology Sales on the Rise Source: EvaluatePharma
More informationDomanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato
Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Ennio Ongini Nicox Consiglio Nazionale delle Ricerche Quarta Giornata Informativa "Dalla ricerca al Trasferimento
More informationTechnology funding opportunities at the National Cancer Institute
Technology funding opportunities at the National Cancer Institute Through the Cancer Diagnosis Program http://cancerdiagnosis.nci.nih.gov/index.html Avraham Rasooly Ph.D. National Cancer Institute, Cancer
More informationOPKO Health to Acquire Bio-Reference Laboratories
OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationEven we will get to use your product someday. Enough reason for us to deliver.
Even we will get to use your product someday. Enough reason for us to deliver. ClinInvent: Putting our heart and soul behind the research. At ClinInvent, when we talk about clinical research it s not just
More informationMYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME
FOR IMMEDIATE RELEASE MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME - $185 Million Collaboration to Determine All Human Protein Interactions And Decipher Biochemical Pathways
More informationCommonwealth Advanced Data Analytics Alliance & The President s Precision Medicine Initiative
Commonwealth Advanced Data Analytics Alliance & The President s Precision Medicine Initiative Deputy Secretary Anthony Fung Presentation to the Health IT Standards Advisory Committee December 17, 2015
More informationPivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform
PRESS RELEASE Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform Pivot Park Screening Centre in Oss will play an important role in a new pan-european drug
More informationRoche Diagnostics Driving Personalized Healthcare
r his presentation contains certain forward-looking statements. hese forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationRichard T. Clark Chief Executive Officer and President. Executing on Our Strategy
Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS
More informationBuilding innovative drug discovery alliances. Introducing JChem for SharePoint at Evotec
Building innovative drug discovery alliances Introducing JChem for SharePoint at Evotec Evotec AG, Introducing JChem for SharePoint at Evotec, 22 nd May 2012 Agenda About Evotec About SharePoint SharePoint
More informationDr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
More informationCraig Hallum Conference Investor Presentation
Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationPharmD Postdoctoral Fellowship Program
Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the
More informationBayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to
More informationORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS
ORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS INCORPORATE GENOMIC DATA INTO CLINICAL R&D KEY BENEFITS Enable more targeted, biomarker-driven clinical trials Improves efficiencies, compressing
More informationRio de Janeiro, Dec 10 th., 2015
Rio de Janeiro, Dec 10 th., 2015 Brazil & The Netherlands - 59% of Dutch import from Latin-America comes from Brazil; - 47% of Dutch total export to Latin-America goes to Brazil - The Netherlands 4 th
More informationDear Business Development or Corporate Alliance Director/Manager,
Korea Drug Research Association(KDRA) and Korea Health Industry Development Institute(KHIDI) cordially request the potential global outsourcing partners(cros, CMOs, CSOs & Consulting Firms) having contract
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationTransforming relationships Unleashing innovation
Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries
More informationRegulatory Issues in Genetic Testing and Targeted Drug Development
Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types
More informationBusiness Information for R&D and Strategic Planning
Business Information for R&D and Strategic Planning Identifying Issues and Selecting Sources Shaida Dorabjee Information Consultant shaida@sdis.co.uk www.sdis.co.uk Pharma-Bio-Med, Dubrovnik. 2-5 November
More informationIntroduction to Q10 Pharmaceutical Quality System
ICH-GCG Asean Training Workshop on ICH Guidelines Q8,Q9 and Q10 (New Paradigm) Introduction to Q10 Pharmaceutical Quality System Georges FRANCE, Q- IWG Kuala Lumpur, Malaysia 26-28 July 2010 International
More informationCDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis
CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society
More informationPress release Regulated information
IBA TRADING UPDATE - THIRD QUARTER 2014 Louvain-La-Neuve, Belgium, 13 November 2014 - IBA (Ion Beam Applications S.A., EURONEXT), the world s leading provider of proton therapy solutions for the treatment
More informationRutgers Mini-MBA : BioPharma Innovation
Rutgers Mini-MBA : BioPharma Innovation Ga i n t h e s k i l l s to t r a n s f o r m scientific i n n ovat i o n i n to business success www.cmd.rutgers.edu/innovation Rutgers Mini-MBA : BioPharma Innovation
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationTERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
More informationHow FDA Promotes Partnerships to Accelerate Medical Product Development
How FDA Promotes Partnerships to Accelerate Medical Product Development ShaAvhrée Buckman-Garner, MD, PhD Director, Office of Translational Sciences Center for Drug Evaluation and Research Food and Drug
More informationThe National Institute of Genomic Medicine (INMEGEN) was
Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the
More informationNormand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada
Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D Globalization of Clinical Research: Trends & Implications for Success Rates by Phase and Therapeutic Area Source: Nature Reviews Drug
More informationCurriculum Policy of the Graduate School of Engineering
Curriculum Policy of the Graduate School of Engineering Graduate School of Engineering: Several specific study goals have been established based on the Degree Awarding Policy of the Graduate School of
More informationThe Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals
The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical
More informationBuilding innovative drug discovery alliances. Addressing causes not. symptoms in diabetes
Building innovative drug discovery alliances Addressing causes not symptoms in diabetes Evotec AG, Analyst information on CureBeta Alliance with Janssen, Hamburg, 2012 Forward-looking statements Information
More informationHow To Improve The Pharmaceutical Industry In Japanese
Pharmaceutical business innovation through utilization of EMR Abstract The pharmaceutical industry in Japan is in a transformation phase due to the government s tightening control over healthcare expenditure
More informationElectronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management
Written Notice of Participation by the Clinical Data Interchange Standards Consortium (CDISC) and Written Statement for Discussion Topics to be Addressed In the FDA Public Hearing: Electronic Submission
More informationVISION STATEMENT. Guiding principles:
VISION STATEMENT Overview The University of Nevada, Las Vegas (UNLV) School of Medicine will address the well-identified need to further advance healthcare in Southern Nevada and establish the foundation
More informationComputational Biomarker Discovery in the Big Data Era: from Translational Biomedical Informatics to Systems Medicine
Computational Biomarker Discovery in the Big Data Era: from Translational Biomedical Informatics to Systems Medicine Bairong Shen Center for Systems Biology Soochow University Bairong.Shen@suda.edu.cn
More informationGLOBAL ACCESS LICENSING FRAMEWORK
GLOBAL ACCESS LICENSING FRAMEWORK Every university-developed technology with potential for further development into a drug, vaccine, or medical diagnostic should be licensed with a concrete and transparent
More informationOverview of the EHR4CR project Electronic Health Record systems for Clinical Research
Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Dipak Kalra UCL on behalf of the EHR4CR Consortium ENCePP Plenary Meeting, 3rd May 2012, London The problem (as addressed
More informationTaking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened
More informationSarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota 55403 612.202.6805 shaecker@celltherapygroup.com
Sarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota 55403 612.202.6805 shaecker@celltherapygroup.com PROFILE Successful Senior Executive, skilled in Corporate Development including Business
More informationMSc program Pharmaceutical Design and Engineering. Peter Heegaard, Head of Studies DTU Veterinary
MSc program Peter Heegaard, Head of Studies DTU Veterinary There is a need for Pharma graduates Pharma industry in its widest sense (see next slide) Research institutions (public and private) Consultants
More informationOracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries
Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be
More informationKobe Medical Industry Development Project. Takashi MIKI Director, Planning and Coordination Bureau City of Kobe
Kobe Medical Industry Development Project Takashi MIKI Director, Planning and Coordination Bureau City of Kobe 0 Where is KOBE? GERMANY JAPAN KOBE 6 th largest city in Japan Population: approx. 1.5 million
More informationA Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field
A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcare
More informationEuropean Industrial Doctorate a win-win collaboration
Content: 18 Slides (15 20 min) Cover, index, contact, Conference anouncement & end: 4 slides Info about GSK DDW: 5 slides Industrial Doctorate: 9 slides 1. PEOPLE (FP7) & MSCA EIDs and ITNs. 2. The Industrial
More informationJoint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
More informationNutraceutical Medical Research, LLC. By: Latesha Richards, Marketing Coordinator
The Value of Conducting Post-Marketing Clinical Research On Marketing Strategy Development Nutraceutical Medical Research, LLC By: Latesha Richards, Marketing Coordinator Those of us who are marketing
More informationUsing Project Management Information Systems (PMIS) To Improve R&D Portfolio Decisions
Massachusetts Biotechnology Council Cambridge, MA Using Project Management Information Systems (PMIS) To Improve R&D Portfolio Decisions Martin D. Hynes III, Ph.D. Director, Operations & Quality, Pharmaceutical
More information